Have you conducted research in the field of 3D cell culture in 2023, utilizing an ibidi product?
If so, seize the opportunity to apply for the ibidi Paper Award 2024! Submit your paper today for a chance to
be recognized for your contributions to 3D cell culture. An external jury will carefully evaluate submissions
and select the winners for a prize of 500 €! Your work will also be featured on ibidi’s website.
Eligible participants include early career researchers (undergraduate, postgraduate
students, postdocs, junior investigators, or assistant professors).
Applicants must be the first or last author of a paper published in 2023 within the field of 3D
cell culture.
The submitted paper must cite an ibidi product.
Publications must be in English and published in peer-reviewed journals.
The deadline for submission is 30 April 2024.
Selection Process
All submitted papers will undergo a meticulous preselection process conducted by ibidi.
Subsequently, an external panel of experts will choose the top three publications from the
preselected papers. Please note that all decisions made by the jury are final and are not open to
legal appeal.
Meet the Jury
Andreas Bausch, Ph.D.
Technical University of Munich, Germany
Prof. Bausch holds currently the Chair of Cellular Biophysics and is the
Founding Director of the Center of Protein Assemblies at the Technical
University of Munich. Since 2022 he has been founding director of the
Center of Organoid Systems and Tissue Engineering at the TUM. After
studying physics at TUM and the Université de Montréal, he received his
doctorate at TUM (1999). An Emmy Noether scholarship enabled him to
study at Harvard University under Prof. D. Weitz. After receiving many
invitations from around the world, Prof. Bausch accepted the Chair of
Cellular Biophysics at TUM in 2008. He had a visiting Miller Professor
Appointment at the University of California, Berkeley (2015) and since
2021 he is a Visiting Scholar at Harvard University. His work targets a
quantitative understanding of the mechanical properties of the
cytoskeleton, and the microscopic mechanisms of self-organization on
the molecular as well on the organoid scale, to which end he developed
a range of active matter systems.
Mina Gouti, Ph.D.
Max Delbrück Center for Molecular Medicine, Berlin, Germany
Dr. Mina Gouti is a group leader at the Max Delbrück Center for
Molecular Medicine in Berlin, where she works at the interface of
developmental biology, stem cell research, and organoid technologies.
She earned her Master's degree in Molecular Medicine from Imperial
College London and later obtained her PhD in Stem Cells and
Developmental Biology from the Biomedical Research Foundation of the
Academy of Athens under the guidance of Dr. A. Gavalas. During her
postdoctoral research at the Francis Crick Institute in James Briscoe's lab,
Dr. Gouti developed an innovative method for the in vitro generation of
neuromesodermal progenitors from pluripotent stem cells. Building on
this foundational work, her lab has pioneered the generation of 3D
human neuromuscular organoids (NMOs) from human pluripotent stem
cell-derived neuromesodermal progenitor cells. This groundbreaking
achievement represents the first human organoid model where all the
components of a functional neuromuscular junction are generated in 3D.
Her contributions to the scientific community have been recognized
through numerous accolades, including being named an EMBO Young
Investigator and receiving prestigious grants such as the ERC
Consolidator Grant and an ERC Proof of Concept grant.
Ryuji Morizane, MD, Ph.D.
Harvard Medical School, Boston, USA
Dr. Ryuji Morizane, a physician-scientist at Massachusetts General
Hospital and Harvard Medical School, specializes in renal research,
particularly focusing on translational studies using human pluripotent
stem cells (hPSCs) for kidney diseases and drug discovery. His pioneering
work since 2007 in pluripotent stem cell research led to the development
of protocols for inducing kidney lineage cells and generating nephron
progenitor cells and kidney organoids from hPSCs with remarkable
efficiency. Notably, Dr. Morizane's innovative approach involves
combining organoid and bioengineering technology to create kidney
organoids with vascular structures, representing a significant
advancement in renal research. This groundbreaking research promises
new insights into kidney development and disease pathogenesis, earning
him the NIH Director’s New Innovator Award in 2019 and establishing
him as a leading expert in the field.